These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25996067)

  • 1. Re-positioning protein-kinase inhibitors against schistosomiasis.
    Gelmedin V; Dissous C; Grevelding CG
    Future Med Chem; 2015; 7(6):737-52. PubMed ID: 25996067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing apoptosis-inducing cancer drugs to treat schistosomiasis.
    Lee EF; Fairlie WD
    Future Med Chem; 2015; 7(6):707-11. PubMed ID: 25996064
    [No Abstract]   [Full Text] [Related]  

  • 3. Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective?
    Dissous C; Grevelding CG
    Trends Parasitol; 2011 Feb; 27(2):59-66. PubMed ID: 20920890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinases as potential targets for novel anti-schistosomal strategies.
    Beckmann S; Leutner S; Gouignard N; Dissous C; Grevelding CG
    Curr Pharm Des; 2012; 18(24):3579-94. PubMed ID: 22607148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting kinases in Plasmodium and Schistosoma: Same goals, different challenges.
    Doerig C; Grevelding CG
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1637-43. PubMed ID: 25770683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study progress on the mode of action of praziquantel against schistosomes].
    Xiao SH
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Dec; 25(6):492-502. PubMed ID: 18441900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.
    Vale N; Gouveia MJ; Rinaldi G; Brindley PJ; Gärtner F; Correia da Costa JM
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward organometallic antischistosomal drug candidates.
    Hess J; Keiser J; Gasser G
    Future Med Chem; 2015; 7(6):821-30. PubMed ID: 25996072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insight into praziquantel against various developmental stages of schistosomes.
    Wu W; Wang W; Huang YX
    Parasitol Res; 2011 Dec; 109(6):1501-7. PubMed ID: 21984370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Histone deacetylase and histone acetyltransferase inhibitors as antischistosomal agents: a review].
    Wang Y; Xu J; Xia C
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2024 Mar; 36(2):207-214. PubMed ID: 38857968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schistosomiasis control: praziquantel forever?
    Cioli D; Pica-Mattoccia L; Basso A; Guidi A
    Mol Biochem Parasitol; 2014 Jun; 195(1):23-9. PubMed ID: 24955523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computationally-guided drug repurposing enables the discovery of kinase targets and inhibitors as new schistosomicidal agents.
    Giuliani S; Silva AC; Borba JVVB; Ramos PIP; Paveley RA; Muratov EN; Andrade CH; Furnham N
    PLoS Comput Biol; 2018 Oct; 14(10):e1006515. PubMed ID: 30346968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Repurposing and De Novo Drug Discovery of Protein Kinase Inhibitors as New Drugs against Schistosomiasis.
    Pereira Moreira B; Weber MHW; Haeberlein S; Mokosch AS; Spengler B; Grevelding CG; Falcone FH
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schistosomiasis: challenges for control, treatment and drug resistance.
    Fenwick A; Webster JP
    Curr Opin Infect Dis; 2006 Dec; 19(6):577-82. PubMed ID: 17075334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in the Synthesis of Antischistosomal Drugs and Agents.
    Liu LX; Li-Li J; Qiong C; Xiao-Lin F
    Mini Rev Med Chem; 2017; 17(5):467-484. PubMed ID: 24251801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing pharma assets: an accelerated mechanism for strengthening the schistosomiasis drug development pipeline.
    Ramamoorthi R; Graef KM; Dent J
    Future Med Chem; 2015; 7(6):727-35. PubMed ID: 25996066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The redox biology of schistosome parasites and applications for drug development.
    Huang HH; Rigouin C; Williams DL
    Curr Pharm Des; 2012; 18(24):3595-611. PubMed ID: 22607149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the treatment of schistosomiasis.
    Lago EM; Silva MP; Queiroz TG; Mazloum SF; Rodrigues VC; Carnaúba PU; Pinto PL; Rocha JA; Ferreira LLG; Andricopulo AD; de Moraes J
    EBioMedicine; 2019 May; 43():370-379. PubMed ID: 31027918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will new antischistosomal drugs finally emerge?
    Cioli D; Valle C; Angelucci F; Miele AE
    Trends Parasitol; 2008 Sep; 24(9):379-82. PubMed ID: 18675590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches for understanding mechanisms of drug resistance in schistosomes.
    Greenberg RM
    Parasitology; 2013 Oct; 140(12):1534-46. PubMed ID: 23552512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.